Updated April 2026
Biosimilar Tracker — The Generic Revolution for Biologics
Biosimilars are near-identical copies of biologic drugs that cost 5-90% less than the original. There are now 19+ biosimilars available in the US across 4 reference drugs, projected to save Medicare over $100 billion in the next decade. Track every biosimilar, its discount, and whether your pharmacist can substitute it automatically.
What Are Biosimilars?
Biologic drugs are made from living cells — they're complex proteins that can't be copied exactly like small-molecule generics. A biosimilar is a biologic that is "highly similar" to an already-approved reference product with no clinically meaningful differences in safety, purity, or potency.
Interchangeable biosimilars have met an even higher standard: the FDA has determined they can be substituted at the pharmacy without the prescribing doctor's involvement — just like a generic drug. Look for the "Interchangeable" badge in the tables below.
Humira Biosimilars
Adalimumab · AbbVie · Autoimmune Diseases
| Biosimilar | Manufacturer | Launch | Discount | Est. Price | Interchangeable |
|---|---|---|---|---|---|
| Hadlima | Samsung Bioepis/Organon | Jul 2023 | -85% | ~$512.10 | No |
| Hyrimoz | Sandoz | Jul 2023 | -80% | ~$682.80 | Yes |
| Simlandi | Teva | Jun 2024 | -80% | ~$682.80 | Yes |
| Cyltezo | Boehringer Ingelheim | Jul 2023 | -78% | ~$751.08 | Yes |
| Idacio | Fresenius Kabi | Jul 2023 | -75% | ~$853.50 | No |
| Yusimry | Coherus | Dec 2023 | -72% | ~$955.92 | No |
| Amjevita | Amgen | Jan 2023 | -55% | ~$1,536.30 | No |
Stelara Biosimilars
Ustekinumab · Johnson & Johnson · Autoimmune Diseases
| Biosimilar | Manufacturer | Launch | Discount | Est. Price | Interchangeable |
|---|---|---|---|---|---|
| Wezlana | Sandoz/Amgen | Feb 2025 | -90% | ~$776.30 | No |
| Pyzchiva | Samsung Bioepis | Mar 2025 | -65% | ~$2,717.05 | No |
| Selarsdi | Teva | Jun 2025 | -55% | ~$3,493.35 | No |
| Otulfi | Fresenius Kabi | Jul 2025 | -50% | ~$3,881.50 | No |
| Imuldosa | Celltrion | Sep 2025 | -45% | ~$4,269.65 | No |
Enbrel Biosimilars
Etanercept · Amgen · Autoimmune Diseases
| Biosimilar | Manufacturer | Launch | Discount | Est. Price | Interchangeable |
|---|---|---|---|---|---|
| Erelzi | Sandoz | Apr 2023 | -50% | ~$2,100.00 | No |
| Hadlima (etanercept) | Samsung Bioepis | Jan 2024 | -45% | ~$2,310.00 | No |
| Eticovo | Samsung Bioepis | Apr 2023 | -35% | ~$2,730.00 | No |
Keytruda Biosimilars
Pembrolizumab · Merck · Cancer
Various Insulin Products Biosimilars
Insulin (multiple types) · Eli Lilly, Novo Nordisk, Sanofi · Diabetes
| Biosimilar | Manufacturer | Launch | Discount | Est. Price | Interchangeable |
|---|---|---|---|---|---|
| Insulin Lispro (authorized generic) | Eli Lilly | Jan 2023 | -75% | ~$75.00 | Yes |
| Rezvoglar | Eli Lilly | Dec 2023 | -70% | ~$90.00 | No |
| Semglee | Viatris/Biocon | Nov 2021 | -65% | ~$105.00 | Yes |
| Insulin Glargine-yfgn | Sandoz | Mar 2024 | -60% | ~$120.00 | No |
Frequently Asked Questions
A biosimilar is a biologic product that is highly similar to an already-approved reference biologic with no clinically meaningful differences. Think of it as the "generic" version of a biologic drug, though the manufacturing process is more complex than traditional generics.
Yes. The FDA requires biosimilars to demonstrate no clinically meaningful differences from the reference product in safety, purity, and potency. They undergo extensive testing including analytical studies, animal studies, and clinical trials.
An interchangeable biosimilar can be substituted for the reference product by a pharmacist without the prescribing doctor's involvement — just like a generic drug. This is a higher standard than "biosimilar" alone and requires additional switching studies.
Discount levels depend on competition, market dynamics, and PBM negotiations. Humira biosimilars initially launched with small discounts due to rebate arrangements with insurance companies, but as more competitors enter the market, discounts have increased dramatically. Stelara's Wezlana biosimilar launched at 90% off.
Biosimilars are projected to save Medicare over $100 billion over the next decade. Humira biosimilars alone could save $10B+ over 5 years. Combined with IRA-negotiated prices, the savings from the biosimilar wave could transform drug affordability for millions of patients.